NCI-2024-02774

A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

This is a Phase 3 study called DeLLphi-305, testing a combination of two drugs, Tarlatamab and Durvalumab, compared to Durvalumab alone, in people with Small-Cell Lung Cancer (SCLC). The patients in this study have already been treated with chemotherapy drugs like Platinum and Etoposide, along with Durvalumab. Tarlatamab is a new drug that helps the immune system recognize and attack cancer cells by targeting a specific protein on the cancer cells. Durvalumab is an immune therapy drug that helps the immune system fight cancer by blocking a protein on the cancer cells that stops immune cells from attacking. Platinum-based chemotherapy uses drugs with platinum to kill cancer cells by damaging their DNA, and Etoposide is another chemotherapy drug that stops cancer cells from dividing and growing. The study aims to see if combining Tarlatamab with Durvalumab is more effective than Durvalumab alone for treating this type of lung cancer.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

small cell lung cancer (SCLC): A type of lung cancer with small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06211036

Clinical Trial Site: Einstein

To see all available clinical trials click here.